Vitamin E (alpha-tocopherol)

Vitamin E is a family of fat-soluble compounds (four tocopherols and four tocotrienols) of which alpha-tocopherol is the form humans use. UK adult NRV is 12 mg/day; the only EFSA-authorised UK health claim is that vitamin E "contributes to the protection of cells from oxidative stress" at ≥15 % NRV. Dietary deficiency is rare in the UK because vitamin E is widespread in vegetable oils, nuts, and seeds. High-dose vitamin E supplementation (≥400 IU/day, ~268 mg α-TE) is associated with measurable harms in long-term randomised trials — increased all-cause mortality (Miller 2005 meta-analysis), increased heart-failure risk (HOPE-TOO), and a non-significant signal of increased prostate cancer (SELECT). The honest position is: NRV-level vitamin E from diet or a multivitamin is unproblematic; high-dose vitamin E is not.

Camden Medicals editorial · Last reviewed 11 June 2026 · Next review June 2027

  • Cross-checked against
  • NHS
  • NICE
  • BNF
  • EFSA
  • FSA
Verifera Evidence ReviewCamden evidence review · independently appraised — graded, not guessed.

Camden's editorial team independently graded each health claim below on the strength of the published evidence — see the grade beside every condition.

Class
Vitamin
Typical daily dose
Most adults: dietary intake ~6-12 mg/day; multivitamin top-up at 100 % NRV (12 mg) is appropriate. Health-claim threshold is 1.8 mg α-TE (15 % NRV) per portion. Doses ≥400 IU/day (≈268 mg natural α-TE) are NOT recommended outside a specific clinical context.
Top use evidence
Strong
On this page
  1. What it is
  2. How it works

What it is

"Vitamin E" is a family name for eight fat-soluble compounds — four tocopherols (α, β, γ, δ) and four tocotrienols (α, β, γ, δ) — that share a chromanol-ring antioxidant chemistry. The dominant form in human plasma and the only one the body actively retains is α-tocopherol, because the liver's α-tocopherol transfer protein (α-TTP) selectively reincorporates α-tocopherol into VLDL particles for redistribution. The other tocopherols and tocotrienols are absorbed but cleared faster.

Dietary sources are predominantly vegetable oils (sunflower, safflower, wheat-germ), nuts (almonds, hazelnuts), seeds (sunflower), and avocado. Whole-grain cereals and dark leafy vegetables contribute smaller amounts. The British diet rarely produces vitamin E deficiency — it appears almost exclusively in fat-malabsorption states (cystic fibrosis, cholestatic liver disease, short-bowel syndrome, abetalipoproteinaemia) where targeted prescription supplementation is indicated.

Supplements come as natural-source (RRR-α-tocopherol or "d-alpha-tocopherol") or synthetic (all-rac-α-tocopherol or "dl-alpha-tocopherol"). RRR is one stereoisomer; all-rac is a 1:1:1:1:1:1:1:1 mixture of the eight possible stereoisomers, of which only RRR is fully retained by α-TTP. By international convention, 1 mg of RRR-α-tocopherol = 1 mg α-TE = ~1.49 IU; for synthetic all-rac, 1 IU = 0.45 mg α-TE (about half the per-milligram activity of the natural form, per NIH ODS conversions). UK supplement labels increasingly declare both formats. Mixed-tocopherol preparations preserve the natural plant-oil profile and are the closer-to-food option, but the regulatory health claim and the NRV are written for α-TE only.

At a glance

  • UK NRV = 12 mg α-tocopherol equivalent (α-TE) per day. Most UK adults get enough from diet; clinical deficiency is rare and usually secondary to fat-malabsorption (cystic fibrosis, cholestasis, abetalipoproteinaemia).
  • One UK-authorised health claim under Regulation (EU) 432/2012: "Vitamin E contributes to the protection of cells from oxidative stress" (≥15 % NRV / 1.8 mg α-TE per portion).
  • "More is not better." Three large randomised trials (HOPE-TOO 2005, SELECT 2008, Miller 2005 meta-analysis) found high-dose vitamin E supplements (≥400 IU/day) associated with increased mortality, heart failure, or non-significant prostate cancer signals. NRV-tier intake is safe.
  • Forms matter. RRR-α-tocopherol ("d-alpha", from natural sources) has roughly 1.5× the activity per mg of all-rac-α-tocopherol ("dl-alpha", synthetic). UK labels typically express dose as α-TE to normalise across forms.
  • Drug interactions: high-dose vitamin E increases bleeding risk on warfarin. Stay at NRV-level intake or stop high-dose vitamin E ~1 week before scheduled surgery.

What people use it for

  • Adults with a varied UK diet

    Most adults meet vitamin E NRV (12 mg α-TE) through normal eating — vegetable oils used in cooking and dressings, nuts, seeds, avocado. A standard multivitamin providing 100 % NRV (12 mg) is unproblematic; high-dose single-nutrient vitamin E supplements are not generally recommended. [2]

    Popular, not provenInsufficient

  • Adults eating a low-fat / low-oil diet, or with restricted-variety diets

    Vitamin E is fat-soluble and absorption depends on dietary fat. Very low-fat diets, or dietary patterns excluding oils, nuts, seeds, and dairy, can leave vitamin E intake below NRV. A multivitamin at NRV bridges the gap; megadose supplementation is not warranted. [1]

    Some evidenceLimited

  • Patients with confirmed fat-malabsorption (cystic fibrosis, cholestatic liver disease, abetalipoproteinaemia, short-bowel)

    This is a prescribed-medication context. Targeted vitamin E supplementation under specialist supervision is established practice — paediatric metabolic-medicine and gastroenterology teams set the dose. Self-supplementation is not appropriate here. [6]

    Some evidenceStrong

  • Adults considering high-dose vitamin E (≥400 IU/day) for general prevention or "wellness" framing

    The published evidence is against doing this. The HOPE-TOO trial found higher heart-failure risk with 400 IU/day for ~7 years; the SELECT trial found a non-significant prostate-cancer signal at the same dose; the Miller 2005 meta-analysis (135,967 participants across 19 trials) concluded high-dose vitamin E (≥400 IU/day) "may increase all-cause mortality and should be avoided". UK clinical guidance does not recommend high-dose vitamin E for general cardiovascular or cancer prevention. [7,8,9]

    Some evidenceStrong

How it works

Alpha-tocopherol is the principal lipid-phase chain-breaking antioxidant in cell membranes — it donates a hydrogen atom to lipid peroxyl radicals, terminating peroxidation propagation, and is itself recycled by ascorbate (vitamin C) and the glutathione system. This is the molecular basis of the EFSA-authorised "protection of cells from oxidative stress" claim; it is a cellular biochemistry claim, not a clinical-outcome claim.

Common myths

Myth""Vitamin E prevents heart disease.""

RealityThe opposite. The HOPE-TOO trial of 400 IU/day natural-source vitamin E in vascular-disease/diabetes patients over 7 years found NO cardiovascular benefit and an INCREASED risk of heart failure. UK clinical guidance does not recommend vitamin E for cardiovascular prevention. [7]

Myth""Vitamin E prevents cancer.""

RealityTwo large RCTs (SELECT in men, ATBC in male smokers) failed to show cancer-preventive benefit; SELECT showed a non-significant signal of MORE prostate cancer; ATBC showed more haemorrhagic-stroke deaths. UK supplement marketing cannot make cancer-prevention claims. [8,10]

Myth""More vitamin E is better.""

RealityThe Miller 2005 meta-analysis showed dose-dependent harm signals starting above ~150 IU/day, with statistically significant all-cause mortality increase at ≥400 IU/day. NRV-level intake (12 mg α-TE) from diet or a multivitamin is the safe and evidence-based default. [9]

Myth""Natural vitamin E is the same as synthetic.""

RealityPartly true, partly not. Natural RRR-α-tocopherol has roughly 1.5× the activity per mg of synthetic all-rac-α-tocopherol because the body's α-tocopherol transfer protein selectively retains the RRR stereoisomer. Labels using "α-TE" already correct for this; labels in IU need conversion (1 IU natural = 0.67 mg α-TE; 1 IU synthetic = 0.45 mg α-TE, per NIH ODS). For the same dose in α-TE, natural and synthetic deliver the same active dose — the difference matters only when comparing IU figures.

Common online questions

Synthesised from the questions UK shoppers most often ask online about Vitamin E (alpha-tocopherol). Each answer is editorial and links to its evidence in the Sources list below.

How much vitamin E should I take?

UK NRV is 12 mg α-TE per day. Most adults get this from a varied diet that includes vegetable oils, nuts, seeds, and avocado. A multivitamin providing 100 % NRV is unproblematic; high-dose vitamin E supplements (≥400 IU/day) are NOT recommended for general health and have been associated with measurable harms in large randomised trials. [1,9]

Is high-dose vitamin E good for skin or "youthful appearance"?

No UK-authorised health claim supports skin-rejuvenation or "youthful skin" wording for vitamin E. Topical vitamin E is widely used in cosmetics and there is no harm signal there at cosmetic doses; high-dose oral vitamin E for skin is not evidence-supported and carries the harms documented in HOPE-TOO and Miller 2005. [7,9]

Can I take vitamin E with warfarin?

Only with prescriber input. High-dose vitamin E (≥400 IU/day) interferes with vitamin K-dependent clotting factor regeneration and increases bleeding risk on warfarin. NRV-level vitamin E from a multivitamin is generally fine, but tell your anticoagulation clinic about ALL supplements you take. Stop high-dose vitamin E about a week before scheduled surgery. [6]

Are tocotrienols better than tocopherols?

There is laboratory evidence that gamma-tocotrienol has distinct biological effects, including some that alpha-tocopherol does not share. The clinical-outcome evidence in humans is preliminary. UK regulatory frameworks (NRV, authorised claim, upper intake) are written for alpha-tocopherol equivalents; tocotrienol products are sold legally as food supplements but cannot make the EFSA "protection from oxidative stress" claim unless they meet the α-TE threshold.

⚖️ The official position

What may lawfully be claimed about Vitamin E (alpha-tocopherol) in Great Britain. This is a regulatory position, not an evidence grade.

A health claim is authorised in Great Britain.

“Vitamin E contributes to the protection of cells from oxidative stress”

This claim is authorised for use in Great Britain under the GB Nutrition and Health Claims regulation. A product may carry it when it provides at least 15% of the UK NRV per recommended daily portion.

Authorised UK health claims

Verbatim from the GB Nutrition and Health Claims Register (Reg 432/2012 as assimilated in GB). A product can carry these claims when it provides at least 15% of the UK NRV per recommended daily portion.

1 authorised claim — show / hide
  • "Vitamin E contributes to the protection of cells from oxidative stress"

🔬 Camden’s evidence review

The research Camden reviewed, graded on its strength. This is our own appraisal — it sits beneath the official guidance above, never above it.

  1. Cellular antioxidant function (basic biochemistry)

    StrongEvidencestrong

    Vitamin E's role as the main lipid-phase chain-breaking antioxidant is established cell biochemistry. This is the basis of the EFSA-authorised health claim, set under Regulation (EU) 432/2012 at a threshold of ≥15 % NRV per portion. The claim is mechanistic ("contribution to protection of cells from oxidative stress"), not an outcome claim about disease. [2]

  2. Cardiovascular event prevention

    LimitedEvidencelimited

    The HOPE and HOPE-TOO trials randomised ~9,500 vascular-disease and diabetic patients to natural-source vitamin E 400 IU/day or placebo. Long-term (median 7 years) follow-up showed no reduction in cardiovascular events; vitamin E was associated with INCREASED heart-failure risk (RR 1.13, 95 % CI 1.01-1.26, P = .03) and more heart-failure hospitalisations. UK clinical guidance does not recommend vitamin E supplementation for cardiovascular prevention. [7]

  3. Cancer prevention

    LimitedEvidencelimited

    SELECT (Lippman 2008, n = 35,533 men) randomised relatively healthy older men to vitamin E 400 IU/day, selenium, both, or placebo for a planned 7-12 years. Median 5.5-year follow-up showed no benefit for prostate cancer prevention; the vitamin E arm had a non-significant signal of INCREASED prostate cancer risk (P = .06). The earlier ATBC trial (Heinonen 1994, 29,133 male Finnish smokers) found alpha-tocopherol 50 mg/day did not reduce lung cancer; it was associated with more haemorrhagic-stroke deaths. Vitamin E supplementation is not a permitted UK cancer-prevention claim. [8,10]

  4. All-cause mortality at high doses (≥400 IU/day)

    ModerateEvidencemoderate

    Miller 2005 meta-analysis pooled 19 randomised trials (135,967 participants) and found a statistically significant increase in all-cause mortality at vitamin E doses ≥400 IU/day (risk difference +39 per 10,000 persons, 95 % CI 3-74, P = .035), with a dose-response signal beginning above ~150 IU/day. Concluded: "High-dosage vitamin E supplements may increase all-cause mortality and should be avoided." This finding is contested but is now part of the mainstream framework for setting upper-intake limits. [9,11]

  5. Age-related macular degeneration (AREDS / AREDS-2)

    ModerateEvidencemoderate

    In the AREDS and AREDS-2 trial designs (US National Eye Institute), a fixed-dose multi-nutrient formulation containing vitamin E, vitamin C, zinc, copper, and lutein/zeaxanthin slowed progression to advanced AMD in patients with intermediate AMD by ~25 % over 5 years. This is a specific clinical use case (intermediate AMD, ophthalmologist-supervised) using a defined formulation — not a general indication for vitamin E supplementation. [12,13,14]

Safety

NRV-tier vitamin E (≤12 mg/day from supplements, plus a varied diet) is well-tolerated and broadly beneficial as part of normal nutrition. High-dose vitamin E (≥400 IU/day, ~268 mg α-TE) carries documented harm signals — increased heart-failure risk on long-term use (HOPE-TOO), all-cause mortality dose-response (Miller 2005), and a non-significant prostate-cancer signal (SELECT). High-dose vitamin E also increases bleeding risk on warfarin.

Talk to your pharmacist or GP first if you:

  • You take warfarin or other anticoagulants — high-dose vitamin E interferes with vitamin K-dependent clotting and increases bleeding risk.
  • You take antiplatelet therapy (aspirin, clopidogrel) — additive bleeding risk at high doses.
  • You have heart failure or established cardiovascular disease — long-term vitamin E ≥400 IU/day was associated with worsened heart-failure outcomes in HOPE-TOO.
  • You are scheduled for surgery — stop high-dose vitamin E ~1 week beforehand.
  • You take ciclosporin or other immunosuppressants — possible pharmacokinetic interaction.
  • You have fat-malabsorption (cystic fibrosis, cholestasis, short-bowel) — your specialist team should set vitamin E dose; do not self-supplement.

Common side effects: At NRV-tier intake, virtually none. At high doses, GI upset, fatigue, headache; long-term high-dose use carries the trial-documented harm signals above.

Pregnancy and breastfeeding

Vitamin E at NRV (12 mg α-TE/day) from food or a pregnancy-formulated multivitamin is appropriate; targeted high-dose vitamin E in pregnancy is not recommended without specialist input.

NRV-tier intake during breastfeeding is appropriate. Lactation NRV is the same as adult NRV.

Talk to your GP, midwife, or pharmacist before starting any supplement during pregnancy or breastfeeding.

More clinical detail (for clinicians and informed readers)

Contraindications

  • Active bleeding disorders or imminent surgery (high-dose only).
  • Known hypersensitivity to vitamin E or capsule excipients.

Drug interactions

  • Warfarin / other vitamin-K-antagonist anticoagulants — high-dose vitamin E (≥400 IU/day) increases bleeding risk via interference with vitamin K-dependent clotting; INR monitoring and dose review needed.
  • Aspirin / clopidogrel / other antiplatelets — additive bleeding-risk at high doses.
  • Ciclosporin — vitamin E may alter ciclosporin pharmacokinetics; specialist supervision if both prescribed.
  • Statins — limited evidence that very high vitamin E doses may modestly attenuate the HDL-raising effect of niacin/statin combinations; clinical relevance unclear at NRV-tier intake.
  • Cytotoxic chemotherapy and radiotherapy — antioxidant supplements during treatment should be cleared with the oncology team; some regimens depend on oxidative-stress mechanisms.

This is not an exhaustive list. Always tell your prescriber and pharmacist about every supplement you take.

Common side effects

  • well-tolerated.
  • GI symptoms (nausea, diarrhoea), fatigue, headache, blurred vision occasionally reported.

Rare side effects

  • Bleeding events on concurrent warfarin or antiplatelet therapy.
  • Allergic reactions to soft-gel capsule excipients (rare).

How to take it

Typical supplemental range
Most adults: dietary intake ~6-12 mg/day; multivitamin top-up at 100 % NRV (12 mg) is appropriate. Health-claim threshold is 1.8 mg α-TE (15 % NRV) per portion. Doses ≥400 IU/day (≈268 mg natural α-TE) are NOT recommended outside a specific clinical context.
Timing
With a meal containing fat, for absorption.

How to spot quality

Look for

  • Form named explicitly: "RRR-α-tocopherol" or "d-alpha-tocopherol" (natural) or "all-rac-α-tocopherol" / "dl-alpha-tocopherol" (synthetic). "Vitamin E" alone does not tell you which.
  • Dose declared in α-TE (mg) and IU, with NRV % stated.
  • Mixed-tocopherol products: the four tocopherol contributions broken out (α, β, γ, δ) — useful for consumers wanting the natural plant-oil profile.
  • Clear absence of unnecessary fillers; soft-gel capsule shells declared (gelatin vs vegan-cellulose).
  • GMP-certified manufacture; batch-dated stability declaration (vitamin E oxidises slowly).

Red flags

  • Doses well above NRV (e.g. 400 IU / 268 mg) sold for "youthful skin", "heart health", or "cancer prevention" framing — these claims are not authorised and the evidence base is against high-dose use.
  • "Antioxidant" or "free radical" wording without the authorised "contributes to protection of cells from oxidative stress" wording — these alternatives are not permitted under the EFSA cluster opinion on antioxidant claims.
  • No form named ("Vitamin E 1000 IU") — you cannot work out the actual α-TE dose without knowing natural vs synthetic.
  • Megadose vitamin E marketed for cardiovascular or cancer prevention — explicitly contradicted by HOPE-TOO, SELECT, and Miller 2005.
  • Vitamin E + warfarin or other anticoagulants without a prescriber-supervision warning on the label.

Commonly combined with

Other ingredients that share a biological pathway, cofactor relationship, or evidence-backed protocol with this one. Mechanisms below cite primary physiology — not folk pairing. Doses are literature ranges, not recommendations. Talk to your pharmacist or GP before changing your stack, especially if you take prescription medication.

Vitamin C

Moderate evidence

Antioxidant pair — vitamin C regenerates oxidised α-tocopherol via redox cycling.

α-tocopherol scavenges lipid peroxyl radicals (becomes tocopheroxyl radical); ascorbic acid donates electron to regenerate active α-tocopherol. UK Article 13.1 vitamin E cell-protection + vitamin C oxidative-stress claims.

Evidence: UK Article 13.1 claims for both. [2,2]

Doses studied: 12 mg vitamin E + 80-1000 mg vitamin C daily.

Selenium

Moderate evidence

Antioxidant cluster — vitamin E + selenium GPX cofactor.

Vitamin E lipid-membrane peroxyl-radical scavenging; selenium GPX detoxifies lipid hydroperoxides. Mechanism complementary.

Evidence: UK Article 13.1 cell-protection claims for both. [2,2]

Doses studied: 12 mg vitamin E + 100-200 µg selenium daily.

Found in Camden: Purifera™ Selenium 200µg L-Selenomethionine 120 Capsules

Fish Oil (Long-Chain Omega-3 EPA / DHA, Marine Source)

Moderate evidence

PUFA-stability pair — vitamin E protects fish oil PUFA from peroxidation.

α-tocopherol scavenges lipid peroxyl radicals in PUFA-rich oils. Co-formulation supports oxidative stability of fish oil EPA/DHA.

Evidence: Mechanism well-established. [2]

Doses studied: 12 mg vitamin E + 1000-2000 mg fish oil daily (often co-formulated).

Evening Primrose Oil (Oenothera biennis)

Limited evidence

Polyunsaturated-fatty-acid antioxidant pairing — vitamin E protects PUFA from peroxidation.

α-tocopherol scavenges lipid peroxyl radicals in PUFA-rich membranes. Co-formulation supports oxidative stability of EPO GLA + storage. UK Article 13.1 vitamin E cell-protection claim authorised.

Evidence: UK Article 13.1 vitamin E claim authorised. [2]

Doses studied: 1000-2000 mg EPO + 12 mg vitamin E daily.

Ginkgo Biloba (leaf extract)

Limited evidence

Cardiovascular / cognitive antioxidant cluster — both ginkgo flavonoids and vitamin E feature in mixed-evidence cognitive-decline supplementation.

Ginkgo flavonoid + terpene-lactone signalling on platelet activation factor; vitamin E lipophilic antioxidant. Different mechanisms; commonly co-formulated.

Evidence: UK Article 13.1 vitamin E cell-protection claim authorised. [2]

Doses studied: 120-240 mg ginkgo standardised extract (24% flavone glycosides + 6% terpene lactones) + 12 mg vitamin E daily.

Melatonin (Topical, skin-antioxidant context)

Limited evidence

Lipophilic-antioxidant cluster sibling.

α-tocopherol scavenges lipid peroxyl radicals; melatonin scavenges multiple lipid-phase ROS species + cyclic 3-hydroxymelatonin cascade. Mechanism-additive on lipid-membrane antioxidant axis.

Evidence: Mechanism complementary; co-formulation common. [2]

Doses studied: PM: 0.5-1% melatonin + 1-2% α-tocopherol.

Vitamin A (retinol and provitamin-A carotenoids)

Moderate evidence

Fat-soluble vitamin antioxidant cluster.

Vitamin A + vitamin E both fat-soluble lipid-membrane stability. UK Article 13.1 cell-protection claim for vitamin E.

Evidence: UK Article 13.1 vitamin E claim authorised. [2]

Doses studied: 800 µg vitamin A + 12 mg vitamin E daily (often co-formulated).

Vitamin C topical (L-ascorbic acid + ester derivatives)

Moderate evidence

The classic antioxidant trio (with ferulic acid). Vitamin C regenerates oxidised tocopherol via redox cycling — Skinceuticals CE Ferulic 15% LAA + 1% α-tocopherol + 0.5% ferulic acid is the foundational dermatology product (Pinnell 2005).

α-tocopherol (vitamin E) scavenges lipid peroxyl radicals in cell membranes, becoming the tocopheroxyl radical. Ascorbic acid donates an electron to regenerate active α-tocopherol — redox cycling that extends the antioxidant capacity of both molecules. Ferulic acid stabilises both vitamins (antioxidant + free-radical-scavenging) and contributes its own UV-protective effect.
Pinnell 2005 (Dermatologic Surgery) demonstrated 4-fold increased UV-protective antioxidant capacity in human skin with the LAA + α-tocopherol + ferulic acid trio vs LAA alone. Skinceuticals CE Ferulic is the most-trialled UK / US dermatology vitamin C product.

Evidence: Pinnell 2005 trio evidence foundational. Skinceuticals product RCTs supportive. [2]

Doses studied: 15% LAA + 1% α-tocopherol + 0.5% ferulic acid, AM application. Camden vitamin-e covers the oral vitamin E side.

Related ingredients

Verifera™ is published by Camden Medicals — a UK supplement retailer. We have a commercial interest in some of the ingredients described here; we declare it on every page and our editorial process forbids adjusting copy to favour our own products. Read our editorial policy.

This page is information, not medical advice. Talk to your pharmacist or GP before starting any supplement, especially if you take prescribed medicines, are pregnant or breastfeeding, or have an existing condition.

Suspected side effects can be reported to the MHRA via the Yellow Card scheme: yellowcard.mhra.gov.uk